What "Reasonably" Could Have Been Raised in an Inter Partes Review?

06 April 2016 IP Litigation Current Blog

Since their introduction, inter partes review (“IPR”) proceedings have had a close association with district court litigation. Indeed, litigation defendants are often the petitioners who initiate IPR proceedings. Therefore, the effect that an IPR can have on concurrent or potential litigation is an important consideration for petitioners.

Among the factors that petitioners must consider are the IPR estoppel provisions. In particular, 35 U.S.C. § 315(e)(2) dictates that once the Patent Trial and Appeal Board (“PTAB”) has issued a final written decision on a patent’s claim(s), an IPR petitioner may not assert “that the claim is invalid on any ground that the petitioner raised or reasonably could have raised during that post-grant review.” Section 315(e)(2) estoppel seemingly narrows the scope of the invalidity defenses that may be asserted not only in subsequent district court litigation, but also subsequent International Trade Commission proceedings.

While previously the subject of some ambiguity, the scope of § 315(e) estoppel, and the meaning of “reasonably could have been raised,” has been illuminated by at least one recent district court decision.

In Clearlamp, LLC v. LKQ Corporation, No. 12-cv-2533 (N.D. Ill.) (Mar. 18, 2016), the defendant, LKQ, filed an IPR petition that the PTAB instituted on grounds that included a combination of certain prior art. The PTAB subsequently issued a final written decision that some of Clearlamp’s patent claims were unpatentable, but the PTAB also found that LKQ had not met its burden to demonstrate unpatentability as to other claims.

Back in district court, LKQ attacked the remaining claims by combining the prior art used during the IPR with a datasheet for a “UVHC3000” product that LKQ obtained through third party discovery after the IPR was completed. On summary judgment, Clearlamp argued that LKQ was estopped from presenting the same prior art combination as in the IPR along with the supplemental datasheet, because, according to Clearlamp, § 315(e)(2) estops the assertion of “redundant” grounds, i.e., grounds based on the same reasoning, in district court, and because the UVHC3000 product was known to LKQ prior to its IPR petition.

The district court first found that § 315(e) does not estop grounds merely because they are “redundant” of grounds asserted in the IPR. The district court noted, by the language of statute:

[t]he relevant inquiry. . . is not whether the ground is redundant of a ground that was asserted but, rather, whether the ground reasonably could have been raised [emphasis added]. Merely being redundant to a ground that could have been asserted during inter partes review does not estop the alleged infringer from relying upon a ground based upon prior art that was not reasonably available during inter partes review.

In view of this standard, addressing Clearlamp’s next argument, the district court found that “the datasheet can be used in civil litigation only if it could not have been found by a skilled searcher performing a diligent search.” Furthermore, as the party asserting that estoppel applied, it was Clearlamp’s burden to demonstrate that a skilled searcher would have located the datasheet.

The district court suggested criteria for how Clearlamp might meet its burden, namely “(1) to identify the search string and search source that would identify the allegedly unavailable prior art and (2) present evidence, likely expert testimony, why such a criterion would be part of a skilled searcher’s diligent search.” Finding that estoppel did not apply, the district court noted that at most Clearlamp showed that a search for “UVHC3000” yielded many results, but not the particular datasheet that LKQ obtained in third party discovery (even though the datasheet itself was once a publicly available document).

Ultimately, based on the datasheet and the PTAB’s instructive reasoning, the district court granted summary judgment of invalidity as to the remaining claims.

This decision and the Federal Circuit’s recent decision in Shaw Industries Group, Inc. v. Automated Creel Systems, Inc., No. 2015-1116, 2015-1119 (Fed. Cir. Mar. 23, 2016) , discussed here, appear to narrow the understood scope of § 315(e) estoppel. In particular, the Clearlamp decision highlights a potential way to revive reasoning that the PTAB considered in an IPR. Where third party discovery yields documents that are not otherwise identifiable by a skilled searcher performing a diligent search, estoppel may not apply.

Thus, defendants whose IPR petitions may not have knocked out all the asserted claims should likely explore the possibility of unearthing new information about the art that underlies the IPR grounds, or even art that my augment the IPR grounds. Conversely, the seemingly narrowing scope of § 315(e)(2)’s estoppel may cause plaintiffs to request additional restrictions in litigation stays pending the outcome of a concurrent IPR – for example, that the requestor agree to waive the assertion of § 102 and § 103 defenses should some asserted claims survive.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services


Foley Manufacturing Update
18 August 2022
Manufacturing Industry Advisor
Using Upfront IP Licensing to Reduce Future Supply Chain Disruptions
18 August 2022
Manufacturing Industry Advisor
Do you have adequate Ransomware Cyber Insurance Coverage?
18 August 2022
Internet, IT & e-Discovery Blog
Warning to All U.S. Taxpayers Who Use Cryptocurrency: “Crypto” Doesn’t Mean Your Currency is Secret — or Protected — from the IRS
17 August 2022
Legal News: Government Enforcement Defense & Investigations
Foley Sponsors Ernst & Young Entrepreneur of the Year® Program
1 December 2021 - 30 November 2022
Michigan and Northwest Ohio Region
Moss Adams 2022 Health Care Conference
3-4 November 2022
Las Vegas, NV
An Update on Remote Patient Monitoring Policy and Reimbursement
28 October 2022
Austin, TX
AI in Healthcare: EU-U.S. Legal Challenges and Guidance and Security Implications
26 October 2022
Las Vegas, NV